司美格鲁肽治疗老年2型糖尿病的疗效分析  

Analysis of the efficacy of smegliptide in the treatment of elderly type 2 diabetes mellitus

作　　者：陈思银 李新杰[1] 梅艳洁[1] 周换丽 周玉森[1] CHEN Siyin;LI Xinjie;MEI YanJie;ZHOU Huanli;ZHOU Yusen(Department of Endocrinology,Bozhou People's Hospital,Bozhou 236800,China)

机构地区：[1]亳州市人民医院内分泌科,安徽亳州236800

出　　处：《长春中医药大学学报》2023年第9期1021-1024,共4页Journal of Changchun University of Chinese Medicine

基　　金：安徽省自然科学基金项目(12925K2017B06)。

摘　　要：目的 探究新型长效胰高血糖素样肽-1(GLP-1)类似物司美格鲁肽治疗二甲双胍降糖效果不佳的老年2型糖尿病的有效性和安全性。方法 选取亳州市人民医院内分泌科2021年5月-2022年3月收治的76例二甲双胍降糖效果不佳的老年2型糖尿病患者作为研究对象,采用随机数字表法分为研究组和对照组,各38例。对照组口服二甲双胍片+皮下注射门冬胰岛素30治疗,研究组口服二甲双胍片+司美格鲁肽皮下注射治疗。治疗3个月后评估2组血糖指标、胰岛功能指标、血管内皮指标,记录药物不良反应发生情况。结果 2组治疗3个月后空腹血糖、餐后2 h血糖均低于治疗前,且研究组低于对照组(P <0.05);研究组治疗3个月后血糖达标时间短于对照组(P <0.05);2组治疗3个月后葡萄糖目标范围内时间(TIR)水平均高于治疗前,且研究组高于对照组(P <0.05);2组治疗3个月后胰岛β细胞功能指数(HOMA-β)水平均高于治疗前,胰岛素抵抗指数(HOMA-IR)水平均低于治疗前,且研究组优于对照组(P <0.05);2组治疗3个月后内皮素-1(ET-1)水平均低于治疗前,血管舒张功能(FMD)水平均高于治疗前,且研究组高于对照组(P <0.05)。结论 司美格鲁肽应用于二甲双胍降糖效果不佳的老年2型糖尿病治疗中降糖、控糖效果优越,且安全性良好。Objective To explore the efficacy and safety of a new long-acting glucagon like peptide-1(GLP-1)analogue smegliptide in the treatment of elderly type 2 diabetes mellitus with poor hypoglycemic effect of metformin.Methods 76 elderly patients with type 2 diabetes who had poor hypoglycemic effect of metformin and who were admitted to the Department of Endocrinology of Bozhou People's Hospital from May 2021 to March 2022 were selected as the research objects and divided into the study group and the control group according to random number table method,with 38 cases in each group.The control group was treated with oral metformin tablets and subcutaneous injection of insulin aspart 30,and the study group was treated with oral metformin tablets and subcutaneous injection of smeglutide.After 3 months of treatment,the blood glucose index,pancreatic islet function index and vascular endothelial index of the two groups were evaluated,and the incidence of adverse drug reactions was recorded.Results After 3 months of treatment,the fasting blood glucose and 2-hour postprandial blood glucose levels in both groups were lower than those before treatment,and the study group was lower than the control group(P<0.05);After 3 months of treatment,the time for blood glucose to reach the standard in the study group was shorter than that in the control group(P<0.05);After 3 months of treatment,the time in range(TIR)of glucose within the target range in both groups was higher than that before treatment,and the study group was higher than the control group(P<0.05).After 3 months of treatment,index ofβ-cell function in homeostasis model assessment (HOMA-β) in both groups was higher than those before treatment, and HOMA insulin-resistance (HOMA-IR) index was lower than those before treatment, and the study group was better than the control group (P <0.05);After 3 months of treatment, the levels of endothelin 1 (ET-1) in both groups were lower than those before treatment, and the levels of flow-mediated dilation (FMD) were higher than that b

关 键 词：2型糖尿病 老年 长效GLP-1类似物 司美格鲁肽 

分 类 号：R781.64[医药卫生—口腔医学]